Integer Lawsuit Claims Investors Misled on Electrophysiology Demand

Integer Holdings told investors it was riding a powerful growth wave.
Electrophysiology devices. Pulse field ablation. Strong demand. Clear visibility.
Executives said the future looked brighter every quarter.

But behind that confidence, something was breaking.

Starting in July 2024, Integer repeatedly claimed its heart device business was growing faster than the market. Management said demand was strong and accelerating through 2025. They told investors their electrophysiology products were a major growth driver.

The lawsuit says that was not true. Demand for two key EP devices was already sliding. Growth was slowing. And the company did not tell investors.

Then, on October 23, 2025, the truth came out. Integer cut guidance. Executives admitted adoption of those EP products was slower than expected and would keep dragging into 2026.

The stock collapsed about 32% in a single day.

Investor confidence vanished.

Now, more investors are joining the lawsuit.